Publications by PCC-funded Researchers

Recently Chocair et al published an article in BMC Cancer on research that was funded by a Prostate Cancer Canada Pilot Grant. We’ve provided a synopsis of the results below.

This study showed that prostate tumors without PTEN, a tumor suppressor gene, were associated with a higher risk of cancer recurrence – thus, PTEN loss may indicate which tumours are aggressive. The study also showed that the loss of PTEN was associated with a decrease in androgen receptor (AR), a key protein in the progression of prostate cancer. This may have consequences on cancer response to the commonly used androgen ablation therapy. These findings will be studied in a larger group of patients to fully evaluate the impact of the results. This research is a step toward the development of personalized treatment for prostate cancer based on the molecular characteristics of the tumors.

Full article citation:
PTEN genomic deletion predicts prostate cancer recurrence and is associated with low AR expression and transcriptional activity

Khalil Choucair, Joshua Ejdelman, Fadi Brimo, Armen Aprikian, Simone Chevalier and Jacques Lapointe  
BMC Cancer 2012, 12:543,Published: 22 November 2012 



Dr. John Lewis, a PCC-funded researcher, recently published an article describing breakthroughs in prostate cancer research using nanotechnology. Here’s a snapshot of these recent advances:
Chemotherapies for prostate and other cancers can result in serious side effects. This is because the amount of drug that ends up in the tumour is usually less than 10% of the drug that accumulates in normal tissues. In an article published in the journal Nano Letters, Dr. Lewis and his collaborators describe a new technology that enables the creation of "smart" nanoparticles that seek out cancer cells while avoiding healthy tissues. Prostate Cancer Canada, through its Pilot Grant Program, is supporting Dr. Lewis's group as they use this new technology to test an exciting new "smart" nanoparticle that targets the tumour's blood supply. These nanoparticles should allow us to light up those prostate tumours that are most likely to be lethal, and to deliver chemotherapies directly to the cancer. 

Article Citation:
Discovery of Novel Integrin Ligands from Combinatorial Libraries Using a Multiplex “Beads on a Bead” Approach

Choi-Fong Cho, Giulio A. Amadei, Daniel Breadner, Leonard G. Luyt, and John D. Lewis 

Nano Lett., 2012, 12 (11), pp 5957–5965


Subscribe to our free monthly e-newsletter!

* indicates required

 



PCC Spotlight
New test developed to detect men at high risk of prostate cancer recurrence

Vienna, Austria: A new genetic “signature” to identify prostate cancer patients who are at high risk of their cancer recurring after surgery or radiotherapy has been developed by researchers in Canada, the 33rd conference of the European Society for Radiotherapy and Oncology (ESTRO33) in Vienna will hear today (Saturday). More

CanCertainty for All: Cancer’s Not Fair, But Accessing Treatment Should Be

Toronto, ON – March 10, 2014 – There is no disputing a cancer diagnosis is among the worst news a person or their family could receive. More

$1.8 Million awarded to Movember Rising Stars Supporting Innovators in Prostate Cancer Research

Toronto, ON – February 12, 2014 – Prostate Cancer Canada (PCC) is proud to announce the recipients of its 2014 Movember Rising Star awards in prostate cancer research. More

Support for Those Affected by Prostate Cancer

Toronto, ON - January 28, 2014 – We are pleased to announce a partnership between Prostate Cancer Canada and the Canadian Cancer Society in launching the Prostate Cancer Information Service (PCIS), which provides support to anyone affected by prostate cancer. More


Click here for news archive